Research shows that patients can effectively maintain muscle mass while using Novo Nordisk's weight loss drug Wegovy in combination with Eli Lilly's experimental drug bimagrumab. According to the results announced at the American Diabetes Association's annual meeting held in Chicago on Monday, patients taking the combined medication lost 22.1% of their body weight within 48 weeks, of which 92.8% lost body fat. Notably, 100% of the weight lost in the bimagrumab monotherapy group came from fat, and lean body mass increased by 2.5%.

Research shows that patients can effectively maintain muscle mass while using Novo Nordisk's weight loss drug Wegovy in combination with Eli Lilly's experimental drug bimagrumab. According to the results announced at the American Diabetes Association's annual meeting held in Chicago on Monday, patients taking the combined medication lost 22.1% of their body weight within 48 weeks, of which 92.8% lost body fat. Notably, 100% of the weight lost in the bimagrumab monotherapy group came from fat, and lean body mass increased by 2.5%.